Shopping Cart
- Remove All
- Your shopping cart is currently empty
CHPG is a selective agonist of mGluR5. In BV2 microglial cells, it attenuates SO2-induced oxidative stress and inflammation through the TSG-6/NF-κB pathway.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $123 | 35 days | |
10 mg | $218 | 35 days | |
50 mg | $950 | 35 days |
Description | CHPG is a selective agonist of mGluR5. In BV2 microglial cells, it attenuates SO2-induced oxidative stress and inflammation through the TSG-6/NF-κB pathway. |
In vitro | CHPG (0.5?mM; 30?mins ) protects BV2 cells against SO2-induced apoptosis. CHPG (10-500?μM; 24?hours) significantly increases the cell viability and decreases the LDH release after SO2 derivatives treatment. CHPG (0.5?mM; 30?mins) treatment alone increases the expression of TSG-6 in both mRNA and protein levels [1]. |
In vivo | CHPG (injection; 250 nM; for 7 days) significantly reduces cerebral lesion volume [2]. |
Molecular Weight | 201.61 |
Formula | C8H8ClNO3 |
Cas No. | 170846-74-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.